Advances in the treatment of cytomegalovirus.
British medical bulletin
Oxford University Press
MetadataShow full item record
Krishna, B., Wills, M., & Sinclair, J. (2019). Advances in the treatment of cytomegalovirus.. British medical bulletin, 131 (1), 5-17. https://doi.org/10.1093/bmb/ldz031
Background Human Cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances. Sources of data Recently published research papers and reviews about HCMV treatments. Areas of agreement Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA. Areas of controversy Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection? Growing points Developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP has showed promise in killing both lytically- and latently-infected cells. Areas timely for developing research We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.
Humans, Cytomegalovirus, Cytomegalovirus Infections, Immunoglobulins, Cytomegalovirus Vaccines, Antiviral Agents, Early Diagnosis, Immunosuppression, Perinatal Care, Hematopoietic Stem Cell Transplantation, Organ Transplantation, Virus Latency, Immunity, Cellular, Infant, Newborn, Drug Development
External DOI: https://doi.org/10.1093/bmb/ldz031
This record's URL: https://www.repository.cam.ac.uk/handle/1810/296099
All rights reserved